Cargando…

Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML

Monitoring of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) is predictive of disease recurrence and may identify patients who benefit from treatment intensification. Current MRD techniques rely on multicolor flow cytometry or molecular methods, but are limited in ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Stasik, Sebastian, Burkhard-Meier, Clara, Kramer, Michael, Middeke, Jan M., Oelschlaegel, Uta, Sockel, Katja, Ehninger, Gerhard, Serve, Hubert, Müller-Tidow, Carsten, Baldus, Claudia D., Röllig, Christoph, Bornhäuser, Martin, Platzbecker, Uwe, Thiede, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198930/
https://www.ncbi.nlm.nih.gov/pubmed/35320339
http://dx.doi.org/10.1182/bloodadvances.2021006233
_version_ 1784727751690813440
author Stasik, Sebastian
Burkhard-Meier, Clara
Kramer, Michael
Middeke, Jan M.
Oelschlaegel, Uta
Sockel, Katja
Ehninger, Gerhard
Serve, Hubert
Müller-Tidow, Carsten
Baldus, Claudia D.
Röllig, Christoph
Bornhäuser, Martin
Platzbecker, Uwe
Thiede, Christian
author_facet Stasik, Sebastian
Burkhard-Meier, Clara
Kramer, Michael
Middeke, Jan M.
Oelschlaegel, Uta
Sockel, Katja
Ehninger, Gerhard
Serve, Hubert
Müller-Tidow, Carsten
Baldus, Claudia D.
Röllig, Christoph
Bornhäuser, Martin
Platzbecker, Uwe
Thiede, Christian
author_sort Stasik, Sebastian
collection PubMed
description Monitoring of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) is predictive of disease recurrence and may identify patients who benefit from treatment intensification. Current MRD techniques rely on multicolor flow cytometry or molecular methods, but are limited in applicability or sensitivity. We evaluated the feasibility of a novel approach for MRD detection in peripheral blood (PB), which combines immunomagnetic preenrichment and fluorescence-activated cell sorting (FACS) for isolation of CD34(+) cells with error-reduced targeted next-generation sequencing (NGS). For clinical validation, we retrospectively analyzed 429 PB and 55 bone marrow (BM) samples of 40 patients with AML or high-risk MDS, with/without molecular relapse based on CD34(+) donor chimerism (DC), in complete remission after allogeneic stem cell transplantation. Enrichment of CD34(+) cells for NGS increased the detection of mutant alleles in PB ∼1000-fold (median variant allele frequency, 1.27% vs 0.0046% in unsorted PB; P < .0001). Although a strong correlation was observed for the parallel analysis of CD34(+) PB cells with NGS and DC (r = 0.8601), the combination of FACS and NGS improved sensitivity for MRD detection in dilution experiments ∼10-fold to levels of 10(−6). In both assays, MRD detection was superior using PB vs BM for CD34(+) enrichment. Importantly, NGS on CD34(+) PB cells enabled prediction of molecular relapse with high sensitivity (100%) and specificity (91%), and significantly earlier (median, 48 days; range, 0-281; P = .0011) than by CD34(+) DC or NGS of unsorted PB, providing additional time for therapeutic intervention. Moreover, panel sequencing in CD34(+) cells allowed for the early assessment of clonal trajectories in hematological complete remission.
format Online
Article
Text
id pubmed-9198930
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-91989302022-06-15 Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML Stasik, Sebastian Burkhard-Meier, Clara Kramer, Michael Middeke, Jan M. Oelschlaegel, Uta Sockel, Katja Ehninger, Gerhard Serve, Hubert Müller-Tidow, Carsten Baldus, Claudia D. Röllig, Christoph Bornhäuser, Martin Platzbecker, Uwe Thiede, Christian Blood Adv Myeloid Neoplasia Monitoring of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) is predictive of disease recurrence and may identify patients who benefit from treatment intensification. Current MRD techniques rely on multicolor flow cytometry or molecular methods, but are limited in applicability or sensitivity. We evaluated the feasibility of a novel approach for MRD detection in peripheral blood (PB), which combines immunomagnetic preenrichment and fluorescence-activated cell sorting (FACS) for isolation of CD34(+) cells with error-reduced targeted next-generation sequencing (NGS). For clinical validation, we retrospectively analyzed 429 PB and 55 bone marrow (BM) samples of 40 patients with AML or high-risk MDS, with/without molecular relapse based on CD34(+) donor chimerism (DC), in complete remission after allogeneic stem cell transplantation. Enrichment of CD34(+) cells for NGS increased the detection of mutant alleles in PB ∼1000-fold (median variant allele frequency, 1.27% vs 0.0046% in unsorted PB; P < .0001). Although a strong correlation was observed for the parallel analysis of CD34(+) PB cells with NGS and DC (r = 0.8601), the combination of FACS and NGS improved sensitivity for MRD detection in dilution experiments ∼10-fold to levels of 10(−6). In both assays, MRD detection was superior using PB vs BM for CD34(+) enrichment. Importantly, NGS on CD34(+) PB cells enabled prediction of molecular relapse with high sensitivity (100%) and specificity (91%), and significantly earlier (median, 48 days; range, 0-281; P = .0011) than by CD34(+) DC or NGS of unsorted PB, providing additional time for therapeutic intervention. Moreover, panel sequencing in CD34(+) cells allowed for the early assessment of clonal trajectories in hematological complete remission. American Society of Hematology 2022-06-02 /pmc/articles/PMC9198930/ /pubmed/35320339 http://dx.doi.org/10.1182/bloodadvances.2021006233 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
spellingShingle Myeloid Neoplasia
Stasik, Sebastian
Burkhard-Meier, Clara
Kramer, Michael
Middeke, Jan M.
Oelschlaegel, Uta
Sockel, Katja
Ehninger, Gerhard
Serve, Hubert
Müller-Tidow, Carsten
Baldus, Claudia D.
Röllig, Christoph
Bornhäuser, Martin
Platzbecker, Uwe
Thiede, Christian
Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML
title Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML
title_full Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML
title_fullStr Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML
title_full_unstemmed Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML
title_short Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML
title_sort deep sequencing in cd34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in aml
topic Myeloid Neoplasia
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198930/
https://www.ncbi.nlm.nih.gov/pubmed/35320339
http://dx.doi.org/10.1182/bloodadvances.2021006233
work_keys_str_mv AT stasiksebastian deepsequencingincd34cellsfromperipheralbloodenablessensitivedetectionofmeasurableresidualdiseaseinaml
AT burkhardmeierclara deepsequencingincd34cellsfromperipheralbloodenablessensitivedetectionofmeasurableresidualdiseaseinaml
AT kramermichael deepsequencingincd34cellsfromperipheralbloodenablessensitivedetectionofmeasurableresidualdiseaseinaml
AT middekejanm deepsequencingincd34cellsfromperipheralbloodenablessensitivedetectionofmeasurableresidualdiseaseinaml
AT oelschlaegeluta deepsequencingincd34cellsfromperipheralbloodenablessensitivedetectionofmeasurableresidualdiseaseinaml
AT sockelkatja deepsequencingincd34cellsfromperipheralbloodenablessensitivedetectionofmeasurableresidualdiseaseinaml
AT ehningergerhard deepsequencingincd34cellsfromperipheralbloodenablessensitivedetectionofmeasurableresidualdiseaseinaml
AT servehubert deepsequencingincd34cellsfromperipheralbloodenablessensitivedetectionofmeasurableresidualdiseaseinaml
AT mullertidowcarsten deepsequencingincd34cellsfromperipheralbloodenablessensitivedetectionofmeasurableresidualdiseaseinaml
AT baldusclaudiad deepsequencingincd34cellsfromperipheralbloodenablessensitivedetectionofmeasurableresidualdiseaseinaml
AT rolligchristoph deepsequencingincd34cellsfromperipheralbloodenablessensitivedetectionofmeasurableresidualdiseaseinaml
AT bornhausermartin deepsequencingincd34cellsfromperipheralbloodenablessensitivedetectionofmeasurableresidualdiseaseinaml
AT platzbeckeruwe deepsequencingincd34cellsfromperipheralbloodenablessensitivedetectionofmeasurableresidualdiseaseinaml
AT thiedechristian deepsequencingincd34cellsfromperipheralbloodenablessensitivedetectionofmeasurableresidualdiseaseinaml